Potential impact of expanded insurance coverage for ondansetron on prophylactic antiemetic prescriptions given and postoperative antiemetics delivered among patients undergoing general anaesthesia in Japan: a retrospective observational study using interrupted time-series analysis of a nationwide claims database
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background The impact of expanding health insurance coverage for ondansetron on antiemetic prescription trends and postoperative nausea and vomiting (PONV) in Japan remains unknown. This nationwide Japanese descriptive study evaluated the impact of the coverage expansion on clinical practice and patient outcomes. Methods This large-scale retrospective observational study using an interruped time-series analysis (ITSA) analysed a nationwide health insurance claims database from more than 500 institutions in Japan (February 2020 to March 2024). The primary outcome was prophylactic and rescue antiemetic prescriptions given, and the secondary outcome was PONV the estimated occurence of PONV based on antiemetic treatment. Prescriptions on surgery day and postoperative days 1–2 were used as surrogate measures of prophylactic antiemetic use and pharmacologically treated (rescue-medicated) PONV, respectively; these surrogates were not direct measures of clinically observed PONV. Results A total of 2 150 497 general anaesthesia cases (2 022 695 adults; 127 802 children) were analysed. After coverage expansion, prophylactic antiemetic prescriptions increased (total prescriptions, from 492 998 of 1 052 933 [46.8%] to 636 158 of 1 097 564 [58.0%]; ≥2 prescriptions, from 92 134 of 1 052 933 [8.8%] to 246 572 of 1 097 564 [22.5%]). ITSA showed that ondansetron prescriptions increased significantly after coverage expansion (β=0.33; 95% confidence interval [CI] 0.23–0.43; P <0.001). The combined effect of guideline release and coverage expansion was associated with a significant downward trend in pharmacologically treated PONV (β=−0.050; 95% CI −0.093 to −0.0079; P =0.021). Conclusions Established clinical guidelines and expanded insurance coverage of ondansetron were associated with changes in perioperative antiemetic prescribing and a modest decline in pharmacologically treated PONV in Japan. As a retrospective observational study, causality cannot be confirmed, and further studies are needed to assess generalisability.
Source: BJA Open
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,870
OpenAlex ID: W7235923413
